Side Effects of JAK Inhibitor Therapy: What Patients Should Know

JAK inhibitors have transformed the treatment of dozens of immune-mediated conditions, but they carry a specific safety profile that requires ongoing monitoring and patient education. Because JAK-STAT signaling is central to immune defense against infections, surveillance against malignancy, and hematopoiesis, broadly inhibiting JAK kinases inevitably affects these functions to varying degrees. Understanding the risks, their magnitude, how they are monitored, and what symptoms to report empowers patients to use these effective medications safely.

Infection Risk

Infections are the most common serious adverse events with JAK inhibitor therapy, reflecting the role of JAK-STAT signaling in antiviral and antibacterial immunity. Upper respiratory infections, bronchitis, urinary tract infections, and sinusitis are the most common infections reported, with rates modestly elevated compared to TNF inhibitor therapy. More clinically significant are serious infections (requiring hospitalization or IV antibiotics) and opportunistic infections. Rates of serious infections in JAK inhibitor clinical trials are generally comparable to biologic therapies, occurring in approximately 2–5% of patients per year.

Herpes Zoster

Herpes zoster (shingles) is the most consistently elevated infection risk associated with JAK inhibitors — particularly those inhibiting JAK1 and JAK3, which affect T cell immunity critical for VZV surveillance. The rate of herpes zoster with tofacitinib and upadacitinib is approximately 2–5 events per 100 patient-years, roughly double the background rate in RA and several-fold higher than with TNF inhibitors. Asian patients appear to have higher rates than European patients, consistent with known geographic differences in VZV seroprevalence and reactivation risk. The recombinant adjuvanted shingles vaccine (Shingrix) has 90%+ efficacy in immunocompetent adults and retains meaningful efficacy in immunosuppressed patients — it is strongly recommended (2 doses, 2–6 months apart) before starting JAK inhibitor therapy, ideally at least 2 weeks before the first dose.

The ORAL Surveillance Signal: Cardiovascular and Malignancy Risks

In 2021, results from the ORAL Surveillance study — a post-marketing randomized trial comparing tofacitinib to TNF inhibitors in RA patients aged ≥50 with cardiovascular risk factors — reported that tofacitinib was associated with higher rates of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, CV death) and malignancies (excluding non-melanoma skin cancer) compared to TNF inhibitors. Based on these findings, the FDA updated labeling for all JAK inhibitors approved for inflammatory conditions with a boxed warning about MACE, malignancy, thrombosis, and serious infections, and restricted their use to patients who have had inadequate responses to TNF inhibitors (with exceptions where no adequate alternatives exist).

The absolute risk increase from ORAL Surveillance was relatively modest and was observed in a high-risk population by design (age ≥50, ≥1 CV risk factor). Whether this signal applies equally to younger, lower-risk patients receiving JAK inhibitors for atopic dermatitis or IBD — who may have very different baseline cardiovascular risk — is actively debated. The benefit-risk calculation must be individualized, and the FDA guidance reflects a precautionary regulatory approach rather than a blanket contraindication.

Venous Thromboembolism

An increased risk of venous thromboembolism (VTE — deep vein thrombosis and pulmonary embolism) was first identified with baricitinib at the higher 4 mg dose and was subsequently captured in the ORAL Surveillance data. The mechanism is not fully established but may involve effects on platelet function, regulation of von Willebrand factor, or direct effects on coagulation pathway signaling. Risk factors for VTE (prior VTE, obesity, immobility, oral contraceptive use, surgery) should be assessed before initiating therapy. High-risk patients should generally avoid JAK inhibitors or, if used, receive appropriate VTE prophylaxis during high-risk periods.

Hematologic Monitoring

JAK2-targeting agents (ruxolitinib, pacritinib, momelotinib) cause anemia and thrombocytopenia that require regular CBC monitoring. Pan-JAK inhibitors and JAK1-selective inhibitors produce more modest cytopenias, primarily lymphopenia. Neutropenia is less common but should prompt dose reduction if severe. Lipid levels are elevated by many JAK inhibitors (particularly tofacitinib and baricitinib) — fasting lipid panels should be checked at baseline, 12 weeks after initiation, and then annually, with statin initiation as indicated.

Key Safety Monitoring Schedule

Before starting: CBC, CMP, lipid panel, TB test (QuantiFERON Gold or T-spot), hepatitis B and C serology, herpes zoster vaccination, and cancer screening up to date. At 4–8 weeks: CBC, liver function tests, lipids. Every 3 months: CBC, liver function tests. Annually: CBC, lipid panel, cancer screenings. Report immediately: any signs of serious infection (fever, rigors, productive cough, urinary symptoms with fever), new shingles rash (early antiviral treatment reduces complications), chest pain, severe shortness of breath, leg pain and swelling (possible DVT/PE), or any new skin lesions (for skin cancer surveillance). For the mechanistic basis of JAK inhibitor selectivity and which cytokines are affected, see our article on JAK1 vs JAK2 vs JAK3.

For more information, visit our homepage or our resources section.